The common frequent precursors to head and neck squamous cell carcinoma (HNSCC) are oral dysplasias (ODs). Nonetheless, methods for prediction or prevention of the malignant transformation of OD are unreliable. Therefore, oral HNSCC is often diagnosed in the advanced stages of the disease. Abnormalities in histone acetylation in oral cancers include aberrant histone deacetylase (HDAC) expression. Therefore, HDAC inhibitors (HDACis) have potential in the treatment of HNSCC and chemoprevention for patients with high-risk OD. Valproic acid (VPA), is an anti-epileptic drug that shows HDACi activity, specifically targeting Class IIa HDACs, with efficacy against HNSCC cells; however, the molecular changes in response to VPA remain unclear. The present study aimed to determine how VPA exposure affects Class IIa HDAC mRNA expression in oral cancer cell lines (UM-SCC-10A, UM-SCC-11B, UM-SCC-12, UM-SCC-17A, HN5, PE/CA-PJ15, UM-SCC-1, BHY, PE/CA-PJ41 and UM-SCC-81B) and premalignant cells (D19, D20 and D35). Reverse transcription-quantitative PCR (RT-qPCR) revealed a trend of upregulation of HDAC4 and HDAC5, and downregulation of HDAC7 in all of the examined cells in response to 1 mM VPA exposure at different time points (6, 24 or 48 h). A total of three cell lines (precancerous D20 tongue immortal dysplastic cells, BHY oral squamous cell carcinoma cells and UM-SCC-10A laryngeal squamous cell carcinoma cells; ≥2-fold differences in HDAC expression following VPA treatment) were selected for further investigations using RT-qPCR to confirm the VPA-mediated alteration of HDAC mRNA expression. VPA-dependent epigenetic reprogramming resulted in transcriptional alterations of Class IIa HDACs in HNSCC and premalignant cells. The clinical relevance of these alterations in the pathogenesis of HNSCC must be further determined.
valproic acidoral cancerhistone deacetylase inhibitorprecancerous cellFunding: No funding was received.Introduction
Early diagnosis of oral head and neck squamous cell carcinoma (HNSCC) is key to improving the probability of survival (1,2). However, only 28% of HNSCCs are diagnosed in the local stages of the disease, making treatment more challenging (3). Early diagnosis of oral carcinoma improves the 5-year survival rate to ~85% compared with 40-60% associated with more advanced stages of the disease (4).
Common precursors to oral HNSCC are leukoplakia or erythroplakia, which are white or red lesions of the oral cavity, collectively known as oral dysplasias (ODs) (5) that represent the most common oral potentially malignant disorders (6). Currently, the only method to predict malignant transformation (MT) of ODs is histological grading to categorise lesions as ‘high’ or ‘low’ risk (7). A limitation of this method is its subjectivity, which provides the potential for misdiagnosis. Other methods have been researched, including DNA ploidy analysis (8) and the use of biomarkers (9,10); however, these methods are not currently employed in clinical practice and are potentially invasive due to requiring biopsy. In addition, the only approach to prevent MT is surgical excision, which is invasive and often leads to long-term morbidity, whilst not necessarily excluding recurrence due to its significant association with MT (P<0.001) (11,12).
A notable cause of the late diagnosis of oral carcinoma is the inaccurate prediction and prevention of MT of potentially malignant ODs (7). Moreover, ODs often remain asymptomatic (13). Thus, lesions are left undetected or misdiagnosed and measures are not undertaken to halt development into cancer. There is an unmet clinical need to improve OD management. Chemoprevention is a primary research focus in HNSCC for patients with high-risk OD to slow, stop or regress development of neoplastic disease (14).
There are 18 known histone deacetylases (HDACs), which are divided into four classes based on their sequence structure (15,16). Class IIa represents a set of classical HDACs (HDAC4, HDAC5, HDAC7 and HDAC9), which are dependent on zinc for their enzymatic activity (17).
HDACs are complex enzymes that are yet to be fully understood. HDACs may undergo post-translational modifications, including methylation and ubiquitination, which can alter enzymatic activity (16). This creates functional variability between HDACs and causes distinct subcellular localisation associated with different functions.
HDACs regulate expression of multiple proteins implicated in tumorigenesis, including those involved in processes such as the cell cycle (such as HDAC5-mediated Six1 upregulation), apoptosis (for example, class IIa HDAC inhibition enhances endoplasmic reticulum stress), angiogenesis (such as HDAC9-mediated proangiogenic protein expression) and DNA damage (such as HDAC4-mediated 53BP1 reduction) (18,19). Consequently, aberrant expression of classical HDACs is associated with numerous types of solid (20) and haematological malignancies (21). Upregulation of HDACs is often associated with poor prognosis (22-24). Altered expression of HDACs is dependent on the cancer type and location (25,26). For example, upregulation of HDAC9 has been found in oral cancer (27,28).
HDACs serve as promising targets for cancer therapy. Inhibition of HDACs has notable antitumour effects (29-33). So far, four HDAC inhibitors (HDACis) have been approved by the Food and Drug Administration for clinical use and there are more undergoing clinical trials (34).
Valproic acid (VPA) is a short-chain fatty acid that has been under investigation for head and neck cancer chemoprevention (35). VPA is a commonly used therapy for epilepsy, as well as other neurological disorders (36). VPA has been established as a Class IIa HDACi (37), which impacts its neurological indications but also suggests VPA as a potential agent for cancer treatment. Studies have found promising in vitro and in vivo anticancer effects of VPA, including anti-proliferative effects and decreased cell viability (38,39). Clinical trials are ongoing to determine its use as monotherapy or combination therapy in multiple types of solid (40) and haematological malignancy (41). To date, results indicate an encouraging patient response, particularly when used as an adjuvant therapy to cytotoxic chemotherapy (42).
A study has investigated the association between long-term VPA treatment and the incidence of different types of cancer in US Army veterans with psychiatric conditions (43). VPA prescription was associated with risk reduction of HNSCC (HR, 0.66; 95% CI, 0.48-0.92), while no significant differences in cancer incidence were identified for malignancies of the lung, colon, prostate and bladder. These results indicate that VPA may serve as a chemo-preventative agent in HNSCC. In addition, certain HDACs such as HDAC1 and HDAC2 are upregulated in potentially malignant ODs (27,44), further supporting the use of HDACis in chemoprevention.
The ongoing SAVER trial conducted by the University of Liverpool (Liverpool, UK) is investigating VPA as a chemo-preventative epigenetic agent in patients with high-risk OD (45). Moreover, a mechanistic study to elucidate molecular changes that occur in response to VPA exposure is being conducted in parallel. To the best of our knowledge, how VPA influences its target genes, including if HDAC expression is altered, remains unclear (46). Previous work investigating HDACis has demonstrated that HDAC expression may be modified following inhibition (47); however, this research is limited to VPA and HNSCC. Mechanisms of other inhibitor drugs include feedback loops (negative/positive), which adjust the expression of respective targets in response to exposure (48). VPA may cause this same response, resulting in altered expression of its target HDAC genes in malignant and premalignant cell lines (46). Therefore, the present study aimed to determine the effect of VPA on Class IIa HDAC expression in oral cancer and premalignant cells.
Materials and methodsCell lines and culture
Cell lines were authenticated (GenePrint 10 System; Promega Corporation) and mycoplasma tested (Myco™ plus Mycoplasma PCR Detection kit; Intron Biotechnology, Inc.). All cancer cell lines were maintained in DMEM/Ham's Nutrient Mixture F-12 (1:1) containing 5% FBS (Sigma-Aldrich; Merck KGaA). Human immortalised bronchial epithelial cells (HBEC-3-KT; cat. no. CRL-4051; American Type Culture Collection) were cultured in keratinocyte-serum-free medium (Thermo Fisher Scientific, Inc.), supplemented with 50 mg/ml bovine pituitary extract and 5 ng/ml human recombinant epidermal growth factor (Thermo Fisher Scientific, Inc.). All cell lines were maintained at 37˚C with 5% CO2.
Human oral cancer cell lines obtained from the Liverpool University Biobank by the Liverpool Head and Neck group (Liverpool, UK) were as follows: Squamous cell carcinoma of larynx (UM-SCC-10A, UM-SCC-11B, UM-SCC-12 and UM-SCC-17A), tongue (HN5, PE/CA-PJ15 and UM-SCC-1), oral cavity (BHY and PE/CA-PJ41) and tonsil (UM-SCC-81B) cell lines (originally from American Type Culture Collection or European Collection of Authenticated Cell Cultures), in addition to three premalignant dysplastic oral mucosa cell lines (D19, D20 and D35) derived at The Beatson Institute for Cancer Research (Glasgow, Scotland) (49). The cells were cultured in 75-cm2 flasks and incubated in DMEM supplemented with 10% FBS at 37˚C with 5% CO2. At 50% confluence, cells were treated, under the same aforementioned culture conditions, with 1 mM VPA (Sigma-Aldrich; Merck KGaA), which is almost 2-fold lower than the estimated IC50 for oral cancer cells (50). Untreated cells were used as the control. After 6, 24 or 48 h of incubation, the cells were washed with phosphate buffer, lysed using 800 ml TRIzol™ (Thermo Fisher Scientific, Inc.) and frozen at -80˚C for RNA extraction.
Cell lines (BHY, D20 and UM-SCC-10A) of most interest (at least ~2-fold differences in HDAC expression following VPA treatment) were selected for further investigation. Each cell line was cultured in 6-well plates and incubated in DMEM supplemented with 10% FBS at 37.5˚C with 5% CO2. After reaching 50% confluence, cells were treated with 1 mM VPA for 6 or 48 h, under the same aforementioned growth conditions. The cells were lysed using 300 ml TRIzol and subsequently frozen for RNA extraction. For 48 h time-point VPA exposure, the medium of 6-well plates was changed after 24 h and fresh VPA (1 mM) was added. Afterwards, the cells were lysed for RNA extraction as aforementioned.
RNA extraction and reverse transcription (RT)
Total RNA was extracted from cells using a Direct-zol™ RNA Miniprep kit (Zymo Research Corp.) according to the manufacturer's protocol. To quantify and qualify the extracted RNA, a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Inc.) was used. The High-Capacity cDNA Reverse Transcription kit (Thermo Fisher Scientific, Inc.) was used for RT of 300 ng RNA according to the manufacturer's instructions.
RT-quantitative (q)PCR
Primers and probes for genes of Class IIa HDACs and the endogenous calibrator β-actin (ACTB) were designed using the OLIGO 7 primer analysis software (Molecular Biology Insights, Inc.) as follows: HDAC4 forward, 5'-TGGGAAACGAGCTTGATCCT-3', reverse, 5'-TGTGGAGGTTGTGCGCTG-3' and probe, 5'-VIC-AGGCAGCGCCAGTACTTGCTGTGG-NFQ-3'; HDAC5 forward, 5'-ATCCAGAGTGCGTGAGGAC-3', reverse, 5'-CATGGCGCTCACAGTCTC-3' and probe, 5'-VIC-CCTCCTCGGTCTCACCTGCTTG-NFQ-3'; HDAC7 forward, 5'-AACCTCAATGCCATCCGCT-3', reverse, 5'-GGTCACTGCCTCCACTTCTTCT-3' and probe, 5'-VIC-TCT GGAGGCCGTGATCCGGGT-NFQ-3'; HDAC9 forward 5'-AACTTGACACGGCAGCAC-3', reverse, 5'-CGATGCCTCTCTACTTCCTGT-3' and probe, 5'-VIC-CTCAGCTTCAGGAGCATATCAAGGAACTT-NFQ-3'; and ACTB forward, 5'-GGCACCCAGCACAATGAAG-3', reverse, 5'-CATACTCCTGCTTGCTGATCCA-3' and probe, 5'-VIC-CTCCTCCTGAGCGCAAGTACTCCGTG-NFQ-3'.
mRNA expression profiles of the tested Class IIa HDAC genes were measured using RT-qPCR with a predesigned TaqMan gene expression assay (Thermo Fisher Scientific, Inc.). The thermocycling conditions were 95˚C for 10 min (initial denaturation), followed by 45 cycles of 95˚C for 15 sec (denaturation) and 60˚C for 1 min (annealing and extension), on a StepOnePlus Real-Time PCR System (Thermo Fisher Scientific, Inc.). For normalisation, ROX dye was added, which reduces the influence of well-to-well variability such as uneven illumination, slight variation in optics and differences in the amount of condensation. All qPCR assays were performed as four technical replicates.
Relative quantification values were calculated to estimate mRNA expression levels according to the 2-ΔΔCq method (51) using StepOne software (version 1.2; Thermo Fisher Scientific, Inc.) and normalised to ACTB. The mean of the 6-h control DCq values for each cell line was used as the exogenous control for further normalisation (ΔΔCq=ΔCq sample-ΔCq 6-h control).
Statistical analysis
To determine differences in Class IIa HDAC mRNA expression, three biological replicates were used and estimated as the mean of their values with their respective 95% confidence intervals. The one-sample Kolmogorov-Smirnov test was used to test the normality of the data. All data were confirmed as non-normally distributed data, and the non-parametric Mann-Whitney U test was used to determine the statistical significance of expression levels. P<0.05 was considered to indicate a statistically significant difference. To investigate the differential expression of HDACs across both treatment and incubation time, Kruskal-Wallis test with post-hoc Dunn test (with Bonferroni correction for multiple testing) was performed for each HDAC in each cell line. All statistical analyses were conducted using SPSS (version 27; IBM Corp.).
ResultsClass IIa HDAC expression in the 13 tested cell lines
Preliminary results regarding the mRNA expression levels of Class IIa HDAC genes indicated variable changes in HDAC transcript levels following VPA exposure. According to the comparisons of HDAC transcript levels independently performed for each of the cell lines tested at each time point [VPA-treated vs. untreated groups (controls)] (Fig. 1), the significance (Mann Whitney test; P<0.05) was inferred to select three cell lines (D20, BHY and UM-SCC-10A) that showed clear and consistent changes in expression (based on 95% CI) across the multiple HDACs, and thus, were chosen for further investigation.
Increased HDAC4 and HDAC5 and decreased HDAC7 mRNA expression was observed across the cell lines, while no consistent, except borderline significant, changes were caused to HDAC9 mRNA expression following VPA treatment compared with controls (Fig. 1).
Following VPA treatment, BHY cells exhibited notable alterations in HDAC expression for HDAC4, HDAC5 and HDAC7, including a 2-fold increase and decrease in HDAC4 and HDAC7 expression, respectively. UM-SCC-10A cells displayed a 2-fold increase in HDAC4 expression for all examined time points, while 2-fold and an 8-10-fold increases in HDAC5 expression for 48 and 6-24 h, respectively, were observed following VPA treatment compared with controls (Fig. 1). A number of the other cell lines also showed changes of interest in the preliminary data. Increased HDAC4 and HDAC5 and decreased HDAC7 mRNA expression trends similar to those in BHY cells were observed in D19 cells for all the tested time points except that at 24 h for HDAC7 expression, in HN5 cells for all the examined time points except at 24 and 48 h for HDAC5 expression, in PE/CA-PJ41 cells for all the investigated time points except for HDAC5 expression, in UM-SCC-12 cells for all the studied time points except for HDAC4 expression, in UM-SCC-11B cells for all the examined time points except at 6 and 48 h for HDAC5 expression, and in UM-SCC-17A cells for all the tested time points except at 6 h for HDAC4 expression.
Class IIa HDAC mRNA expression in BHY, D20 and UM-SCC-10A cells
VPA treatment caused a significant increase in HDAC4 mRNA expression. This was particularly evident at 48 h in BHY (Fig. 2) and UM-SCC-10A cells (Fig. 3), which exhibited an ~2-fold increase in HDAC4 expression. In UM-SCC-10A cells, a significant 2-fold increase in HDAC5 expression occurred following VPA treatment for 6 and 48 h. An increase in HDAC5 expression was observed in BHY cells; however, this was only significant at 6 h (~2.5-fold increase). HDAC5 expression in D20 cells was increased at 6 h but significantly decreased at 48 h (Fig. 4). This result did not correspond with the evident increases in HDAC5 expression seen at all the time points in the preliminary data (Fig. 1). BHY and D20 cells exhibited significant 1.5-2.0-fold decreases in HDAC7 expression at 6 and 48 h. Consistent with the aforementioned data, UM-SCC-10A cells exhibited no significant change in HDAC7 expression following VPA treatment (Table IC). Significant decreases were also observed for HDAC7 in treated BHY and D20 cells (Table IC).
Both VPA treatment and incubation time had an effect on HDAC4 levels (Kruskal-Wallis; P<0.001). In pairwise post hoc analysis (Dunn test), HDAC4 expression significantly increased between 6 and 48 h in both control and treatment groups across all cell lines (P<0.027) (Table SIA). The increase at 48 h was greater for VPA-treated cells (2.66-6.14-fold) than control cells (1.80-2.27-fold) (Table IA), indicating that the combined effect of time and VPA treatment increased HDAC4 expression. However, pairwise post hoc analysis (Dunn test) indicated that the incubation time had a more significant association with the HDAC4 increase than VPA treatment (Table SIA). For HDAC7, the significant decrease seen was also more closely associated with incubation time than VPA exposure; pairwise post hoc tests were significant only for time in all cell lines. Only for HDAC9 was there no association with incubation time.
Discussion
Epigenetic targeted therapy is an approach to chemotherapy and chemoprevention (52). Epigenetic alterations, including aberrant recruitment of HDACs, are observed in potentially malignant lesions and may serve as an indicator of cancer development. Therefore, methods to modify or reverse these alterations, such as HDAC inhibition, may be an approach for effective chemoprevention in high-risk patients (53).
VPA is a potent Class IIa HDACi under investigation for cancer treatment (43), indicating its potential use in HNSCC chemoprevention. Class IIa HDACs are upregulated in HNSCC tissue and potentially malignant ODs (27). To the best of our knowledge, little research has been conducted on molecular changes that occur in response to VPA treatment (47), particularly in oral cancer. It is necessary to determine how VPA alters the expression of its targets to understand its mechanism of action and provide potential predictive markers of the response to VPA.
The present study aimed to expand on a previous feasibility study to determine HDAC expression changes in oral cancer cells in response to 1 mM VPA, a concentration 2-fold lower than the estimated IC50 for oral cancer cells (50), and the lowest dose causing VPA-mediated cytotoxicity and cell arrest (54). In addition, VPA at 1 mM is a clinically meaningful dose (55). The RT-qPCR analyses further confirmed the preliminary significant changes in Class IIa HDAC mRNA expression in BHY, D20 and UM-SCC-10A cells, where the HDAC4 and HDAC5 expression increased and HDAC7 expression decreased (except in UM-SCC-10A cells) following VPA treatment at the tested time points (6 and 48 h). No significant changes were observed for HDAC9 in BHY, D20 and UM-SCC-10A cells after VPA exposure at the examined time points (6 and 48 h). This may suggest that VPA may not target HDAC9 in HNSCC.
The differential expression of HDACs may be due to variation in the protein complexes associated with each HDAC or the genes they target. The high variability between HDACs may result in varied mechanisms of VPA and differences in response dependent on the HDAC and its associated proteins (56).
VPA directly inhibits HDAC proteins. The present results may indicate that the inhibition of HDAC triggered an auto-regulatory feedback loop, resulting in altered RNA expression to compensate for inhibition. This may be a transcriptional signal to modify the number of transcripts or it may be a signal to adjust RNA degradation (for example, by altering microRNA expression). This auto-regulatory system has been suggested for HDACis, including VPA (57,58).
Similarly, the opposing changes in HDAC expression in the present study (the increased HDAC4 and HDAC5 expression and decreased HDAC 7 expression) may also be attributed to a reciprocal regulatory mechanism between HDACs. To compensate for inhibition, the expression of one HDAC may be downregulated to allow the upregulation of another (59,60). A significant decrease in HDAC7 expression was observed in BHY and D20 cells, while there was a significant increase in HDAC4 expression. The aforementioned regulatory mechanisms indicate that VPA may alter the de novo synthesis of HDACs and contribute to epigenetic reprogramming to counteract the loss of function caused by protein inhibition.
HDAC expression in response to HDACis has been investigated in other cancer types such as pancreatic, breast, prostate and lung cancer (19), revealing fluctuations similar to those found in the present study. In addition, there is evidence that expression may change over time. In a previous study, human leukaemia cell line MOLT4 was treated with VPA and HDAC expression was analysed over 5 days; expression of HDAC2, HDAC5, HDAC6, HDAC8 and HDAC9 increased until day 3, then declined (61). Furthermore, a study investigating Class II HDACs in breast cancer found downregulation of HDAC3, HDAC7, HDAC8 and HDAC10 but upregulation of HDAC2 following treatment with Trichostatin-A, a non-selective HDACi (62). These findings suggest that there may be compensatory mechanisms of HDAC expression following inhibition, which differ depending on the cancer type and inhibitor used.
In addition to changes in response to VPA exposure, differences in HDAC expression were observed among different time points. HDAC4 expression significantly increased between 6 and 48 h for control and treated cells across all cell lines, HDAC7 expression decreased in UM-SCC-10A cells and HDAC5 expression increased in D20 cells. The reason for selecting the aforementioned time-points (6 and 48 h) for VPA exposure was to explore the VPA epigenetic effect on HDACs expression compared with the early and late log phase of cellular growth of controls (the growing and surviving cells at 6 and 48 h time-points, respectively). It can be hypothesized that the cell confluence may influence HDAC regulation, as a part of a dynamic epigenetic reprogramming of the cell population. However, this needs to be demonstrated in future experiments to investigate the effect of cell confluence on differential HDAC expression. As growth media with fresh VPA were added at the midpoint (24 h) of the 48 h, the VPA activity was maintained, thus differences are unlikely to be due to VPA degradation; previously it has been shown that VPA does not affect cell viability after 24 h (63). In any case, differential expression of some HDACs in untreated cells at 48 h indicated that cell confluence might also serve a role in differential expression. Incubation time was the most significant factor for changes in HDAC expression, when comparing across all conditions. The present study lacked functional analysis, which is required in the future.
The changes in HDAC expression induced by VPA varied between cell lines. Genotypes and genomic mutation load differ between HNSCC cell lines (64). Therefore, the effect of VPA on HDAC expression may be dependent on the expression and function of numerous gene effectors.
Overall, the present results indicated that VPA-dependent epigenetic reprogramming was associated with transcriptional alterations of Class IIa HDACs in HNSCC and premalignant cells. The role of these alterations in the clinical management of HNSCC must be determined to develop potential epigenetic therapeutic regimens.
Supplementary Material
Kruskal-Wallis test pairwise post hoc analysis (Dunn test) for comparisons of HDAC mRNA expression among the groups of tested cell lines.
Acknowledgements
The authors would like to thank Dr Triantafillos Liloglou (University of Liverpool, Liverpool, UK) for providing the cancer cell lines. The authors would also like to thank Dr Caroline McCarthy and Dr Keith Hunter (University of Liverpool) for gifting the dysplastic cell lines.
Availability of data and materials
The data generated in the present study may be requested from the corresponding author.
Authors' contributions
ASKAK conceived and designed the study, analysed data and wrote the manuscript. YBQ, LMW and HHA interpreted data and revised the manuscript. LMW analysed data. ASKAK, YBQ, HHA and LMW confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Patient consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
ReferencesHoMWFieldEAFieldJKRiskJMRajlawatBPRogersSNSteeleJCTriantafyllouAWoolgarJALoweDShawRJOutcomes of oral squamous cell carcinoma arising from oral epithelial dysplasia: Rationale for monitoring premalignant oral lesions in a multidisciplinary clinicBr J Oral Maxillofac Surg5159459920132360183210.1016/j.bjoms.2013.03.014SciubbaJJOral Cancer. The importance of early diagnosis and treatmentAm J Clin Dermatol223925120011170525110.2165/00128071-200102040-00005National Cancer Institute: Cancer Stat Facts: Oral Cavity and Pharynx Cancer. https://seer.cancer.gov/statfacts/html/oralcav.html.González-MolesMÁAguilar-RuizMRamos-GarcíaPChallenges in the early diagnosis of oral cancer, evidence gaps and strategies for improvement: A scoping review of systematic reviewsCancers (Basel)14496720223623089010.3390/cancers14194967van der WaalIPotentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of managementOral Oncol4531732320091867495410.1016/j.oraloncology.2008.05.016WarnakulasuriyaSOral potentially malignant disorders: A comprehensive review on clinical aspects and managementOral Oncol10210455020203198199310.1016/j.oraloncology.2019.104550FieldEAMcCarthyCEHoMWRajlawatBPHoltDRogersSNTriantafyllouAFieldJKShawRJThe management of oral epithelial dysplasia: The Liverpool algorithmOral Oncol5188388720152619897810.1016/j.oraloncology.2015.06.015ZainiZMMcParlandHMøllerHHusbandKOdellEWPredicting malignant progression in clinically high-risk lesions by DNA ploidy analysis and dysplasia gradingSci Rep81587420183036710010.1038/s41598-018-34165-5Al-KhafajiASPantaziPAcha-SagredoASchacheARiskJMShawRJLiloglouTOverexpression of HURP mRNA in head and neck carcinoma and association with in vitro response to vinorelbineOncol Lett192502250720203219475110.3892/ol.2020.11339RiveraCGallegosRFigueroaCBiomarkers of progression to oral cancer in patients with dysplasia: A systematic reviewMol Clin Oncol134220203287457210.3892/mco.2020.2112BalasundaramIPayneKFAl-HadadIAlibhaiMThomasSBhandariRIs there any benefit in surgery for potentially malignant disorders of the oral cavity?J Oral Pathol Med4323924420142375056610.1111/jop.12088SundbergJKorytowskaMHolmbergEBratelJWallströmMKjellströmEBlomgrenJKovácsAÖhmanJSandLRecurrence rates after surgical removal of oral leukoplakia-A prospective longitudinal multi-centre studyPLoS One14e022568220193181007810.1371/journal.pone.0225682RanganathanKKavithaLOral epithelial dysplasia: Classifications and clinical relevance in risk assessment of oral potentially malignant disordersJ Oral Maxillofac Pathol23192720193111041210.4103/jomfp.JOMFP_13_19SiemianowiczKLikusWDoreckaMWilkRDziubdzielaWMarkowskiJChemoprevention of head and neck cancers: Does it have only one face?Biomed Res Int2018905185420183035637110.1155/2018/9051854ParkSYKimJSA short guide to histone deacetylases including recent progress on class II enzymesExp Mol Med5220421220203207137810.1038/s12276-020-0382-4SetoEYoshidaMErasers of histone acetylation: The histone deacetylase enzymesCold Spring Harb Perspect Biol6a01871320142469196410.1101/cshperspect.a018713AudiaJECampbellRMHistone modifications and cancerCold Spring Harb Perspect Biol8a01952120162703741510.1101/cshperspect.a019521GlozakMASetoEHistone deacetylases and cancerOncogene265420543220071769408310.1038/sj.onc.1210610LiYSetoEHDACs and HDAC inhibitors in cancer development and therapyCold Spring Harb Perspect Med6a02683120162759953010.1101/cshperspect.a026831ZhengYCKangHQWangBZhuYZMamunMAAZhaoLFNieHQLiuYZhaoLJZhangXNCurriculum vitae of HDAC6 in solid tumorsInt J Biol Macromol23012321920233664235710.1016/j.ijbiomac.2023.123219WangPWangZLiuJRole of HDACs in normal and malignant hematopoiesisMol Cancer19520203191082710.1186/s12943-019-1127-7OsadaHTatematsuYSaitoHYatabeYMitsudomiTTakahashiTReduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patientsInt J Cancer112263220041530537210.1002/ijc.20395CaoLLSongXPeiLLiuLWangHJiaMHistone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer: A meta-analysisMedicine (Baltimore)96e766320172876758710.1097/MD.0000000000007663MüllerBMJanaLKasajimaALehmannAPrinzlerJBudcziesJWinzerKJDietelMWeichertWDenkertCDifferential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer-overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progressionBMC Cancer1321520132362757210.1186/1471-2407-13-215QaddooriYBAl-KhafajiASKKhashmanBMAbdulghafourKHThe study of histone deacetylases immunoexpression in relation to regulating vascular endothelial growth factor (VEGF) implicated in malignant progression of colorectal cancerIraqi J Sci66186118752025QaddooriYBAl-KhafajiASKKhashmanBMAbdulghafourKHThe potential role of HDAC1 and HDAC3 Immunoexpression in P53 downregulation and tumor aggressiveness of colon and rectum carcinomas patientsExp Oncol4639340120253998534510.15407/exp-oncology.2024.04.393RastogiBRautSKPandaNKRattanVRadotraBDKhullarMOverexpression of HDAC9 promotes oral squamous cell carcinoma growth, regulates cell cycle progression, and inhibits apoptosisMol Cell Biochem41518319620162699290510.1007/s11010-016-2690-5ChangHHChiangCPHungHCLinCYDengYTKuoMYHistone deacetylase 2 expression predicts poorer prognosis in oral cancer patientsOral Oncol4561061420091895183510.1016/j.oraloncology.2008.08.011KellyWKRichonVMO'ConnorOCurleyTMacGregor-CurtelliBTongWKlangMSchwartzLRichardsonSRosaEPhase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenouslyClin Cancer Res9 (10 Pt 1)35783588200314506144DuvicMTalpurRNiXZhangCHazarikaPKellyCChiaoJHReillyJFRickerJLRichonVMFrankelSRPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood109313920071696014510.1182/blood-2006-06-025999O'ConnorOAHorwitzSMassziTVan HoofABrownPDoorduijnJHessGJurczakWKnoblauchPChawlaSBelinostat in patients with relapsed or refractory peripheral T-Cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) studyJ Clin Oncol332492249920152610124610.1200/JCO.2014.59.2782PiekarzRLFryeRTurnerMWrightJJAllenSLKirschbaumMHZainJPrinceHMLeonardJPGeskinLJPhase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaJ Clin Oncol275410541720091982612810.1200/JCO.2008.21.6150San-MiguelJFHungriaVTYoonSSBeksacMDimopoulosMAElghandourAJedrzejczakWWGüntherANakornTNSiritanaratkulNPanobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trialLancet Oncol151195120620142524204510.1016/S1470-2045(14)70440-1EckschlagerTPlchJStiborovaMHrabetaJHistone deacetylase inhibitors as anticancer drugsInt J Mol Sci18141420172867157310.3390/ijms18071414National Library of Medicine (NIH): Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid (GAMA). NIH, Bethesda, MD, 2018. https://clinicaltrials.gov/study/NCT02608736. Accessed March 16, 2025.RomoliMMazzocchettiPD'AlonzoRSiliquiniSRinaldiVEVerrottiACalabresiPCostaCValproic acid and epilepsy: From molecular mechanisms to clinical evidencesCurr Neuropharmacol1792694620193059225210.2174/1570159X17666181227165722GurvichNTsygankovaOMMeinkothJLKleinPSHistone deacetylase is a target of valproic acid-mediated cellular differentiationCancer Res641079108620041487184110.1158/0008-5472.can-03-0799Duenas-GonzalezACandelariaMPerez-PlascenciaCPerez-CardenasEde la Cruz-HernandezEHerreraLAValproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumorsCancer Treat Rev3420622220081822646510.1016/j.ctrv.2007.11.003SangZSunYRuanHChengYDingXYuYAnticancer effects of valproic acid on oral squamous cell carcinoma via SUMOylation in vivo and in vitroExp Ther Med123979398720162810117610.3892/etm.2016.3907National Library of Medicine (NIH): MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer (MC2TCR). NIH, Bethesda, MD, 2023. https://clinicaltrials.gov/study/NCT04729543?cond=(head%20OR%20neck)%20AND%20cancer&term=(head%20OR%20neck)%20AND%20cancer&intr=Valproic%20Acid&page=1&rank=5). Accessed March 16, 2025.National Library of Medicine (NIH): Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes (REPAIR-MDS). NIH, Bethesda, MD, 2023. https://clinicaltrials.gov/study/NCT04997811?cond=Haematological%20Malignancy&term=Haematological%20Malignancy&intr=Valproic%20Acid&rank=1. Accessed March 16, 2025.BrodieSABrandesJCCould valproic acid be an effective anticancer agent? The evidence so farExpert Rev Anticancer Ther141097110020142501721210.1586/14737140.2014.940329KangHGillespieTWGoodmanMBrodieSABrandesMRibeiroMRamalingamSSShinDMKhuriFRBrandesJCLong-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancerCancer1201394140020142466479210.1002/cncr.28479TheocharisSKlijanienkoJGiaginisCRodriguezJJouffroyTGirodAAlexandrouPSastre-GarauXHistone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: Associations with clinicopathological parameters and patients survivalJ Oral Pathol Med4070671420112145734510.1111/j.1600-0714.2011.01031.xMcCarthyCSaccoJFedeleSHoMPorterSLiloglouTGreenhalfBRobinsonMYoungBCicconiSSAVER: Sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia-a phase II randomised control trial study protocolTrials2242820213422576510.1186/s13063-021-05373-8Al-KhafajiASKWangLMAlabdeiHHLiloglouTEffect of valproic acid on histone deacetylase expression in oral cancer (Review)Oncol Lett2719720243851667910.3892/ol.2024.14330DokmanovicMClarkeCMarksPAHistone deacetylase inhibitors: Overview and perspectivesMol Cancer Res598198920071795139910.1158/1541-7786.MCR-07-0324IskarMCampillosMKuhnMJensenLJvan NoortVBorkPDrug-induced regulation of target expressionPLoS Comput Biol6e100092520102083857910.1371/journal.pcbi.1000925McGregorFMuntoniAFlemingJBrownJFelixDHMacDonaldDGParkinsonEKHarrisonPRMolecular changes associated with oral dysplasia progression and acquisition of immortality: Potential for its reversal by 5-azacytidineCancer Res6247574766200212183435Al-KhafajiASKAlnefaieGAl-ShammariAMValproic acid enhances the paclitaxel activity in respiratory tract cancer cellsJ Contemp Med Sci42082132019LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) MethodMethods2540240820011184660910.1006/meth.2001.1262YooCBJonesPAEpigenetic therapy of cancer: Past, present and futureNat Rev Drug Discov5375020061648534510.1038/nrd1930GuMRenBFangYRenJLiuXWangXZhouFXiaoRLuoXYouLZhaoYEpigenetic regulation in cancerMedComm (2020)5e49520243837487210.1002/mco2.495KaragiannisTCKnHEl-OstaAThe epigenetic modifier, valproic acid, enhances radiation sensitivityEpigenetics113113720061796560710.4161/epi.1.3.2896AvalloneAPiccirilloMCDi GennaroERomanoCCalabreseFRocaMSTatangeloFGranataVCassataACavalcantiERandomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: The REVOLUTION study protocolTher Adv Med Oncol12175883592092958920203284991410.1177/1758835920929589UkeySRamtekeAChoudhuryCPurohitPSharmaPDifferential expression of zinc-dependent HDAC subtypes and their involvement in unique pathways associated with carcinogenesisAsian Pac J Cancer Prev2387788320223534535910.31557/APJCP.2022.23.3.877CastroLMGallantMNilesLPNovel targets for valproic acid: Up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cellsJ Neurochem951227123620051631351210.1111/j.1471-4159.2005.03457.xAjamianFSalminenAReebenMSelective regulation of class I and class II histone deacetylases expression by inhibitors of histone deacetylases in cultured mouse neural cellsNeurosci Lett365646820041523447410.1016/j.neulet.2004.04.087JurkinJZupkovitzGLaggerSGrausenburgerRHagelkruysAKennerLSeiserCDistinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesisCell Cycle1040641220112127052010.4161/cc.10.3.14712PinkerneilMHoffmannMJDeenenRKöhrerKArentTSchulzWANiegischGInhibition of Class I Histone Deacetylases 1 and 2 promotes urothelial carcinoma cell death by various mechanismsMol Cancer Ther1529931220162677220410.1158/1535-7163.MCT-15-0618YangHMaddipotiSQuesadaABohannanZCabrero CalvoMCollaSWeiYEstecioMWierdaWBueso-RamosCGarcia-ManeroGAnalysis of class I and II histone deacetylase gene expression in human leukemiaLeuk Lymphoma563426343320152594446910.3109/10428194.2015.1034705DuongVBretCAltucciLMaiADuraffourdCLoubersacJHarmandPOBonnetSValenteSMaudelondeTSpecific activity of class II histone deacetylases in human breast cancer cellsMol Cancer Res61908191920081907483510.1158/1541-7786.MCR-08-0299KwonHYKangNYDaeHMKimKSKimCHDoSILeeYValproic acid-mediated transcriptional regulation of human GM3 synthase (hST3Gal V) in SK-N-BE(2)-C human neuroblastoma cellsActa Pharmacol Sin29999100520081871816710.1111/j.1745-7254.2008.00847.xLiHWawroseJSGoodingWEGarrawayLALuiVWYPeyserNDGrandisJRGenomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: A rational approach to preclinical model selectionMol Cancer Res1257158220142442578510.1158/1541-7786.MCR-13-0396
mRNA expression levels of Class IIa HDACs in oral cancerous and premalignant cell lines following VPA exposure were compared with untreated counterpart cells at three different time points (6, 24 and 48 h). The P-values of significant differences between the examined groups (HDAC expression in VPA-treated cells compared with untreated controls) were indicated as *P<0.05, **P<0.01 and ***P<0.005. HDAC, histone deacetylase; V, expression in VPA-treated cells; VPA, valproic acid; C, control untreated cells; RQ, relative quantity of mRNA expression; NS, not significant.
Effects of valproic acid treatment on Class IIa HDACs mRNA expression in BHY cell line. ***P<0.005. HDAC, histone deacetylase; RQ, relative quantity of mRNA expression; NS, not significant.
Effects of valproic acid treatment on Class IIa HDACs mRNA expression in UM-SCC-10A cell line. *P<0.05, **P<0.01, ***P<0.005. HDAC, histone deacetylase; RQ, relative quantity of mRNA expression; NS, not significant.
Effects of valproic acid treatment on Class IIa HDACs mRNA expression in D20 cell line. *P<0.05, **P<0.01, ***P<0.005. HDAC, histone deacetylase; RQ, relative quantity of mRNA expression; NS, not significant.
Median RQ values representing mRNA expression of Class IIa HDACs following VPA treatment.
A, HDAC4
BHY
D20
UM-SCC-10A
Group
Median RQ
P-value
Median RQ
P-value
Median RQ
P-value
C6
0.97
<0.01
1.01
0.01
1.02
<0.01
V6
1.29
1.28
1.26
C48
2.27
<0.01
1.97
<0.01
1.80
<0.01
V48
6.14
2.66
3.00
B, HDAC5
BHY
D20
UM-SCC-10A
Group
Median RQ
P-value
Median RQ
P-value
Median RQ
P-value
C6
1.00
<0.01
1.09
0.08
0.99
<0.01
V6
2.53
1.36
2.03
C48
1.16
0.52
2.73
0.02
0.91
0.03
V48
1.39
1.99
1.71
C, HDAC7
BHY
D20
UM-SCC-10A
Group
Median RQ
P-value
Median RQ
P-value
Median RQ
P-value
C6
0.98
<0.01
1.01
<0.01
1.02
0.11
V6
0.46
0.46
0.89
C48
1.06
<0.01
1.12
<0.01
1.44
0.26
V48
0.58
0.63
1.52
D, HDAC9
BHY
D20
UM-SCC-10A
Group
Median RQ
P-value
Median RQ
P-value
Median RQ
P-value
C6
0.89
0.15
1.02
0.20
1.00
0.13
V6
0.67
0.76
0.82
C48
0.98
0.75
0.97
0.15
1.12
0.88
V48
1.12
1.19
1.20
HDAC, histone deacetylase; RQ, relative quantity of mRNA expression; C6, expression in untreated cells (control) after 6 h of incubation; V6, expression in VPA-treated cells after 6 h of incubation; C48, expression in untreated cells (control) after 48 h of incubation; V48, expression in VPA-treated cells after 48 h of incubation; VPA, valproic acid.